Business Context and Reporting Period
This Form 8-K Current Report was filed by Ormat Technologies, Inc. on November 16, 2022. The filing discloses the entry into a material definitive agreement regarding a public underwritten offering of the Company's common stock by a significant shareholder, ORIX Corporation.
Key Financial Metrics and Transaction Details
- Transaction Type: Secondary public offering (shares sold by ORIX Corporation; no new shares issued by the Company).
- Shares Sold: 3,750,000 shares of Common Stock at an offering price of $90.00 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase an additional 562,500 shares.
- Proceeds to Company: $0 (All proceeds from the sale are received by ORIX Corporation).
- Expected Closing Date: On or about November 21, 2022.
Note: This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company's operations.
Material Changes and Agreements
The primary material change is the execution of an Underwriting Agreement with BofA Securities, Inc. and J.P. Morgan Securities LLC as representatives. Additionally, the Company and ORIX entered into a First Amendment to their Registration Rights Agreement. Key terms of the amendment include:
- Requirement for the Company to maintain a shelf registration statement for three years to facilitate future sales by ORIX.
- ORIX retains the right to demand underwritten shelf takedowns for shares with a market value of at least $100 million.
- ORIX agreed to a 180-day lock-up period, agreeing not to sell or transfer shares following the Offering.
Outlook, Risks, and Management Commentary
The filing indicates the Offering is subject to customary closing conditions. The Company has agreed to indemnify the Underwriters against certain liabilities under the Securities Act of 1933. No specific forward-looking guidance, operational risks, or management commentary regarding future financial performance is provided in this specific filing.
Key Facts for Investor Verification
- Verify that the Company received no proceeds from this transaction, as it is a secondary sale by ORIX Corporation.
- Confirm the final closing date and whether the 562,500 share over-allotment option was exercised.
- Review the impact of the 180-day lock-up agreement on ORIX's ability to sell remaining holdings.
- Check subsequent filings for any changes to the Company's capital structure resulting from the potential exercise of the over-allotment option.